Life Science Analytics (LSA)

Overview

Life Science Analytics is a biomedical data company that provides corporate intelligence and research products to life science companies and financial industry professionals. Business development officers, librarians and executives of biomedical companies, as well as vendors and consultants who serve those companies, turn to LSA for their corporate intelligence projects.

Our Products

Financial Reports
These reports contain the company’s contact information, details, business overview, shares information, stock performance history, price and volume figures, dividends, market related data including relative strength, valuation and revenues.

Each report also includes earnings and earnings per share, margin and return ratios, financial strength, growth ratios, day’s sales outstanding, day’s outstanding inventory, cash and short-term investments per share and total common shares outstanding. Finally each report includes quarterly book value per share vs. share price. Much of the information contained in each report is included in both tabular and graphic formats.

Product Pipeline Reports
Each report contains: Business Summary; Contact Information; Selected Financial Data; Company Details; Product Glance (Table/Graph); Disease Hub Classification (Table/Graph); Product Pipeline; Product Catalog; Product Details with Description; Therapeutic Indication; Drug Class; Mechanism of Action; Current Trial; Trial Details; Partnering Details etc; Patent Details (if any); Recent Financings; Trademarks; Deals & Alliances; Management Profile; Recent Updates

Competitor Reports
These report includes a business summary, tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stage of development, and competitors by therapeutic indication. Each report also includes recent company news updates

Deals & Alliances Reports
Each report contains the company’s contact information, business summary, company details, tables, graphs and listings of the number of deals by deal category (product, technology, miscellaneous), stage of development, list of partners, deal types (licensing, marketing, etc.), top deals by deal value, partners based on technology with detailed descriptions of the partner firm where disclosed, partners based on product with detailed descriptions of the partner firm where disclosed, partners in other non-product, non-technology deals, with detailed descriptions of the partner firm and terms when available. Each report also includes M&A statistics and recent partnering news updates by date.

Life Science Analytics (LSA)
 

List of reports from Life Science Analytics (LSA)

< prev 5  6  7  8  9  10  11  12  13  14  next >
Brainfarma Industria Quimica e Farmaceutica Ltda.-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... development, and competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as ...  |  more...
$350.00
Eli Lilly Asia, Inc-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into ...  |  more...
$350.00
Eli Lilly Italia S.p.A.-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into ...  |  more...
$350.00
Lilly Netherlands BV-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into the ...  |  more...
$350.00
Eli Lilly and Trade Co., Ltd-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... development, and competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as ...  |  more...
$350.00
Horus Pharma-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into the predicted ...  |  more...
$350.00
Eli Lilly Norway A.S-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into ...  |  more...
$350.00
Eli Lilly Vostok SA-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into ...  |  more...
$350.00
Eli Lilly Inter-America Inc-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into ...  |  more...
$350.00
Boehringer Ingelheim (Canada) Ltd.-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into ...  |  more...
$350.00
Boehringer Ingelheim Mexico, SA-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into ...  |  more...
$350.00
Roxane Laboratories, Inc.-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into the ...  |  more...
$350.00
MSD Australia-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into the predicted ...  |  more...
$350.00
Merck Sharp & Dohme, IDEA A.G. (MSD)-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... of development, and competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well ...  |  more...
$350.00
Astellas Pharma Hong Kong Co., Ltd-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... development, and competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as ...  |  more...
$350.00
Astellas Pharma Korea, Inc.-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into ...  |  more...
$350.00
Astellas Pharma China Inc.-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into ...  |  more...
$350.00
Tentan AG-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into the predicted ...  |  more...
$350.00
Macronova AB-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into the predicted ...  |  more...
$350.00
Borisov Plant of Medical Substances-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... and competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight ...  |  more...
$350.00
Unipharm, Inc.-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into the predicted ...  |  more...
$350.00
Flordis-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into the predicted likelihood ...  |  more...
$350.00
SOFAR s.p.a.-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into the predicted ...  |  more...
$350.00
Pabianickie Zaklady Farmaceutyczne Polfa S.A.-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... and competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight ...  |  more...
$350.00
RKG Pharma Pvt. Ltd.-Therapeutic Competitors Report
3/14/2011 | published by: Life Science Analytics (LSA)
... competitors by therapeutic indication. The report also includes recent company news updates. Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into ...  |  more...
$350.00
< prev 5  6  7  8  9  10  11  12  13  14  next >